Western Fjords Advanced Technologies ltd. has developed a unique therapeutic prototype which provides a solution to the quest for a curative form of cancer treatment while minimizing systemic side effects.
Disease specificity is accomplished by targeting surface receptors expressed solely on the malignant cells with a recombinant construct, consisting of the respective ligand conjugated to a novel mutant of a human pro-apoptotic sentinel.
To further strengthen this approach, the recombinant construct is produced utilizing a highly advanced yet remarkably direct production system, ensuring optimal secondary and tertiary molecular structure and thus, function.
Furthermore, the construct is secreted into the cell media, allowing for ease of harvest, maximum yield and streamlining of the production process.
The construct described provides several advantages over current therapeutic strategies:
built solely from human subunits, adverse immune reactions are minimized;
by introducing a powerful proapoptotic sentinal into the internal milieu of the malignant cells, apoptosis is induced independent of p53 status, cell-cycle or metabolic rate;
designed for intracerebral infusion, aka convection-enhanced delivery, the blood-brain barrier and systemic side effects are bypassed;
Great emphasis is placed on maximizing the therapeutic window, by tailoring said constructs to disease-specific characteristics, thus focusing lethality solely on abnormal cells with minimum adverse effect to healthy tissue in the vicinity or periphery.
